This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)

07/28/15 - 04:15 PM EDT

Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.

read more >

Other Articles by Adam

Free Reports

Gilead Hep C Sales Under Investor Microscope as Earnings Near Gilead Hep C Sales Under Investor Microscope as Earnings Near

07/13/15 - 12:01 PM EDT

The total number of prescriptions written for Gilead Sciences hepatitis C drugs Sovaldi and Harvoni in the U.S. peaked in March and are now in a consistent downtrend.

read more >
Anacor Prescription Lotion Clears Skin Rash in Late-Stage Test Anacor Prescription Lotion Clears Skin Rash in Late-Stage Test

07/13/15 - 07:35 AM EDT

Anacor intends to seek U.S. approval for a skin rash lotion, crisaborole, in the first half of next year, based on data collected from studies.

read more >
Northwest Bio Shareholders May Have Been Undercut by CEO Northwest Bio Shareholders May Have Been Undercut by CEO

07/09/15 - 12:26 PM EDT

The loans negotiated by CEO Linda Powers to a private firm she controls doesn't appear to violate securities laws, but she may have breached fiduciary duty to Northwest Bio shareholders.

read more >
Previewing the Next Look at Biogen's Alzheimer's Drug Previewing the Next Look at Biogen's Alzheimer's Drug

07/09/15 - 10:31 AM EDT

On Saturday, July 18, Biogen will present updated results from a closely watched clinical trial involving its Alzheimer's drug candidate aducanumab (formerly known as BIIB037).

read more >
Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock

07/07/15 - 07:43 AM EDT

Short sellers -- "manipulative" or otherwise -- are not responsible for Keryx's withering stock price. The problem is Auryxia, the company's kidney dialysis drug.

read more >
Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed

07/07/15 - 07:29 AM EDT

Like other specialty pharmaceutical makers headquartered in tax-friendly countries, Horizon is buying growth.

read more >
Vertex Wins U.S. Approval for New Cystic Fibrosis Drug Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

07/02/15 - 02:36 PM EDT

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.

read more >
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

07/02/15 - 12:54 PM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

06/30/15 - 11:27 AM EDT

The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.

read more >
Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

06/29/15 - 05:10 PM EDT

Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.

read more >
Page 2 of 339
Top Rated Stocks Top Rated Funds Top Rated ETFs